scholarly journals The Current Knowledge of Genetic Susceptibility Influencing Dental Implant Outcomes

Author(s):  
Fabiano Alvim-Pereira ◽  
Claudia Cristina ◽  
Paula Cristina
2013 ◽  
Vol 4 (3) ◽  
pp. 87 ◽  
Author(s):  
Meenu Goel ◽  
Sukant Sahoo ◽  
Sameer Saxena ◽  
Pooja Gandhi

2017 ◽  
Vol 4 (3) ◽  
pp. 215-222
Author(s):  
Mohammed Kola ◽  
Altaf Shah ◽  
Hesham Khalil ◽  
Nehad Harby ◽  
Ahmed Rabah ◽  
...  

Author(s):  
Laura E. Ritenour ◽  
Michael P. Randall ◽  
Kristopher R. Bosse ◽  
Sharon J. Diskin

Oral Oncology ◽  
2011 ◽  
Vol 47 (12) ◽  
pp. 1099-1104 ◽  
Author(s):  
Bodard Anne-Gaëlle ◽  
Salino Samuel ◽  
Bémer Julie ◽  
Lucas Renaud ◽  
Breton Pierre

2003 ◽  
Vol 14 (4) ◽  
pp. 305-316 ◽  
Author(s):  
Thomas Beikler ◽  
Thomas F. Flemmig

Dental clinicians are confronted with an increasing number of medically compromised patients who require implant surgery for their oral rehabilitation. However, there are few guidelines on dental implant therapy in this patient category, so that numerous issues regarding pre- and post-operative management remain unclear to the dental clinician. Therefore, the aim of the present review is to offer a critical evaluation of the literature and to provide the clinician with scientifically based data for implant therapy in the medically compromised patient. This review presents the current knowledge regarding the influence of the most common systemic and local diseases on the outcome of dental implant therapy, e.g., abnormalities in bone metabolism, diabetes mellitus, xerostomia, and ectodermal dysplasias. Specific pathophysiologic aspects of the above-mentioned diseases as well as their potential implications for implant success are critically appraised. In line with these implications, guidelines for pre- and post-operative management that may assist in the successful implant-supported rehabilitation of this patient category are proposed.


2021 ◽  
Vol 12 ◽  
Author(s):  
Julia do Amaral Gomes ◽  
Emilie Willoch Olstad ◽  
Thayne Woycinck Kowalski ◽  
Kristina Gervin ◽  
Fernanda Sales Luiz Vianna ◽  
...  

Since the 1960s, drugs have been known to cause teratogenic effects in humans. Such teratogenicity has been postulated to be influenced by genetics. The aim of this review was to provide an overview of the current knowledge on genetic susceptibility to drug teratogenicity in humans and reflect on future directions within the field of genetic teratology. We focused on 12 drugs and drug classes with evidence of teratogenic action, as well as 29 drugs and drug classes with conflicting evidence of fetal safety in humans. An extensive literature search was performed in the PubMed and EMBASE databases using terms related to the drugs of interest, congenital anomalies and fetal development abnormalities, and genetic variation and susceptibility. A total of 29 studies were included in the final data extraction. The eligible studies were published between 1999 and 2020 in 10 different countries, and comprised 28 candidate gene and 1 whole-exome sequencing studies. The sample sizes ranged from 20 to 9,774 individuals. Several drugs were investigated, including antidepressants (nine studies), thalidomide (seven studies), antiepileptic drugs (five studies), glucocorticoids (four studies), acetaminophen (two studies), and sex hormones (estrogens, one study; 17-alpha hydroxyprogesterone caproate, one study). The main neonatal phenotypic outcomes included perinatal complications, cardiovascular congenital anomalies, and neurodevelopmental outcomes. The review demonstrated that studies on genetic teratology are generally small, heterogeneous, and exhibit inconsistent results. The most convincing findings were genetic variants in SLC6A4, MTHFR, and NR3C1, which were associated with drug teratogenicity by antidepressants, antiepileptics, and glucocorticoids, respectively. Notably, this review demonstrated the large knowledge gap regarding genetic susceptibility to drug teratogenicity, emphasizing the need for further efforts in the field. Future studies may be improved by increasing the sample size and applying genome-wide approaches to promote the interpretation of results. Such studies could support the clinical implementation of genetic screening to provide safer drug use in pregnant women in need of drugs.


2019 ◽  
Vol 26 (10) ◽  
pp. R583-R596 ◽  
Author(s):  
Monia Zidane ◽  
Jean-Baptiste Cazier ◽  
Sylvie Chevillard ◽  
Catherine Ory ◽  
Martin Schlumberger ◽  
...  

The first study establishing exposure to ionizing radiations (IRs) as a risk factor for differentiated thyroid cancer (DTC) was published 70 years ago. Given that radiation exposure causes direct DNA damage, genetic alterations in the different DNA repair mechanisms are assumed to play an important role in long-term IR-induced DNA damage prevention. Individual variations in DNA repair capacity may cause different reactions to damage made by IR exposure. The aim of this review is to recapitulate current knowledge about constitutional genetic polymorphisms found to be significantly associated with DTC occurring after IR exposure. Studies were screened online using electronic databases – only fully available articles, and studies performed among irradiated population or taking radiation exposure as adjustment factors and showing significant results are included. Nine articles were identified. Ten variants in/near to genes in six biological pathways, namely thyroid activity regulations, generic transcription, RET signaling, ATM signaling and DNA repair pathways were found to be associated with radiation-related DTC in these studies. Only seven variants were found to be in interaction with IR exposure in DTC risk. Most of these variants are also associated to sporadic DTC and are not specific to IR-related DTC. In the published studies, no data on children treated with radiotherapy is described. In conclusion, more studies carried out on larger cohorts or on case–control studies with well-documented individual radiation dose estimations are needed to get a comprehensive picture of genetic susceptibility factors involved in radiation-related DTC.


2018 ◽  
Vol 372 (2) ◽  
pp. 287-307 ◽  
Author(s):  
Laura E. Ritenour ◽  
Michael P. Randall ◽  
Kristopher R. Bosse ◽  
Sharon J. Diskin

2015 ◽  
Vol 21 (1) ◽  
pp. 1 ◽  
Author(s):  
MohammedZaheer Kola ◽  
AhmedMahmoud Rabah ◽  
Deepti Raghav ◽  
SehamAli Sabra ◽  
Nehad MohammedH Harby ◽  
...  

1990 ◽  
Vol 54 (11) ◽  
pp. 670-679 ◽  
Author(s):  
M Tavares ◽  
LG Branch ◽  
L Shulman

Sign in / Sign up

Export Citation Format

Share Document